--- name: managing-thyroid-disorders language: en description: Guides thyroid evaluation with TSH interpretation, medication titration, and nodule workup protocols. Use when managing hypothyroidism, evaluating thyroid nodules, or adjusting levothyroxine. tags: - management - primary-care - valuation metadata: author: casemark practice_areas: - Family Medicine - Internal Medicine - Primary Care document_types: - Management Report skill_modes: - Management - Coordination --- # Managing Thyroid Disorders Guides thyroid evaluation with TSH interpretation, medication titration, and nodule workup protocols. ## Why This Skill Exists Thyroid disorders are among the most common endocrine conditions encountered in primary care. Hypothyroidism affects 4.6% of the U.S. population (10.4 million), while hyperthyroidism affects approximately 1.2%. Thyroid nodules are found incidentally in up to 68% of adults on ultrasound, yet only 5-15% are malignant. The ATA (American Thyroid Association) 2015 guidelines for thyroid nodules, the ATA 2012 hypothyroidism guidelines, and the 2016 ATA hyperthyroidism guidelines provide the frameworks for management. Common primary care challenges include over-treating subclinical hypothyroidism, misinterpreting TSH in the context of illness or medication effects, inappropriate thyroid ultrasound ordering, and failing to risk-stratify thyroid nodules. This skill provides structured protocols for TSH interpretation, levothyroxine titration, thyroid nodule workup, and referral criteria to ensure efficient, evidence-based thyroid management. --- ## Checkpoint A: Pre-Draft Intake (Mandatory) 1. What is the presenting concern (abnormal TSH, thyroid nodule, symptoms, medication adjustment)? **Default: [REQUIRED]** 2. What is the most recent TSH and when was it drawn? **Default: [REQUIRED]** 3. Is free T4 available? Free T3? **Default: pending if TSH abnormal** 4. Is the patient currently on levothyroxine or antithyroid medication? Dose and duration? **Default: none** 5. Are there thyroid antibodies on file (TPO, TRAb/TSI)? **Default: not checked** 6. Has a thyroid ultrasound been performed? Results? **Default: not done** 7. Is the patient pregnant, planning pregnancy, or postpartum? **Default: no** 8. What medications or supplements may affect thyroid function or absorption (biotin, iron, calcium, PPI, estrogen)? **Default: per med list** ### Documents to Request - TSH trend (minimum 2-3 values over 6-12 months) - Free T4 and T3 if available - Thyroid antibodies (TPO antibodies, thyroglobulin antibodies, TSI/TRAb) - Thyroid ultrasound report with TI-RADS classification if nodule present - FNA cytopathology report (Bethesda classification) if biopsy performed - Nuclear thyroid scan (I-123 uptake) if hyperthyroidism evaluation - Current medication list highlighting levothyroxine dose and timing - Supplements containing biotin (interferes with thyroid immunoassays) - Pregnancy status and estimated gestational age if applicable --- ## Step 1: TSH Interpretation Framework | TSH (mIU/L) | Free T4 | Diagnosis | Initial Action | |---|---|---|---| | 0.4-4.0 | Normal | Euthyroid | No treatment; recheck if symptomatic | | 4.0-10.0 | Normal | Subclinical hypothyroidism | Repeat in 6-12 weeks; check TPO antibodies | | >10.0 | Normal or low | Overt hypothyroidism | Start levothyroxine | | >4.0 | Low | Overt hypothyroidism | Start levothyroxine | | <0.4 | Normal | Subclinical hyperthyroidism | Repeat in 6-12 weeks; evaluate if persistent | | <0.1 | Normal or high | Overt hyperthyroidism | Check T3, TSI/TRAb; refer endocrinology | | Low | Low | Central hypothyroidism | Pituitary evaluation; MRI; endocrinology referral | **Factors affecting TSH interpretation:** - Biotin supplementation: falsely low TSH and falsely high T4 on some assays; hold biotin 48-72 hours before testing - Acute illness (sick euthyroid / non-thyroidal illness): low T3, variable TSH; recheck 6-8 weeks after recovery - Pregnancy: TSH lower in first trimester (normal range: 0.1-2.5 in T1; 0.2-3.0 in T2/T3 per ATA) - Medications: amiodarone (hypo or hyper), lithium (hypothyroidism), dopamine (suppresses TSH), high-dose glucocorticoids (suppresses TSH) --- ## Step 2: Hypothyroidism Management **Levothyroxine dosing:** - Full replacement: 1.6 mcg/kg/day (ideal body weight) - Starting dose in young, healthy adults: 1.6 mcg/kg/day - Starting dose in elderly or cardiac disease: 25-50 mcg/day; increase by 12.5-25 mcg every 6-8 weeks - Typical doses: 50-200 mcg/day for most adults **Administration instructions** (critical for absorption): - Take on empty stomach, 30-60 minutes before breakfast OR at bedtime (≥3 hours after dinner) - Separate from calcium, iron, PPI, and soy by ≥4 hours - Take consistently (same time, same conditions daily) - Brand vs. generic: either acceptable, but avoid switching between brands/generics without rechecking TSH **Monitoring:** | Phase | TSH Recheck Interval | Target TSH | |---|---|---| | Initial titration | Every 6-8 weeks until at goal | 0.5-2.5 mIU/L for most adults | | Stable dose achieved | Every 6-12 months | 0.5-2.5 mIU/L | | Dose changed or new interfering medication | 6-8 weeks after change | Per target | | Pregnancy | Every 4 weeks through week 20; then at 24 and 30 weeks | Per trimester-specific range; <2.5 in first trimester | | Elderly (>70 years) | Every 6-12 months | 1.0-5.0 mIU/L acceptable; avoid over-treatment | **Subclinical hypothyroidism treatment decision:** - TSH >10: treat regardless of symptoms - TSH 4.0-10.0 with symptoms + positive TPO: reasonable to treat - TSH 4.0-10.0, asymptomatic, TPO negative: observe with repeat TSH in 6-12 months - Pregnancy or planning pregnancy with TSH >2.5: treat per ATA --- ## Step 3: Hyperthyroidism Evaluation **Workup when TSH is suppressed (<0.4):** 1. Confirm with repeat TSH + free T4 + total T3 2. Check TSI or TRAb (Graves disease marker) 3. If etiology unclear: radioactive iodine uptake (RAIU) scan - Diffusely increased uptake → Graves disease - Focal uptake → Toxic adenoma or toxic multinodular goiter - Low/absent uptake → Thyroiditis (subacute, postpartum, medication-induced), exogenous thyroid hormone **Management (primary care role is diagnosis and referral):** - Symptomatic relief: propranolol 10-40mg TID (or atenolol 25-50mg daily) for tachycardia, tremor, anxiety - Refer to endocrinology for definitive treatment decisions (antithyroid drugs, RAI, surgery) - Methimazole preferred over PTU (except first trimester pregnancy); PTU used in thyroid storm - Monitor for agranulocytosis on thionamides: WBC if fever/sore throat; educate patient to seek emergency care --- ## Step 4: Thyroid Nodule Evaluation **ATA risk stratification using ultrasound features (TI-RADS):** | TI-RADS Category | Suspicion | FNA Threshold | Features | |---|---|---|---| | TR1 | Benign | No FNA needed | Simple cyst, purely cystic | | TR2 | Not suspicious | No FNA needed | Spongiform, mixed cystic/solid without suspicious features | | TR3 | Mildly suspicious | FNA if ≥2.5 cm; follow if ≥1.5 cm | Isoechoic/hyperechoic solid without suspicious features | | TR4 | Moderately suspicious | FNA if ≥1.5 cm; follow if ≥1.0 cm | Hypoechoic solid with 1 suspicious feature | | TR5 | Highly suspicious | FNA if ≥1.0 cm; follow if ≥0.5 cm | Hypoechoic + ≥2 suspicious features (microcalcifications, irregular margins, taller-than-wide, rim calcification, ETE) | **Bethesda cytopathology classification:** | Bethesda | Diagnosis | Risk of Malignancy | Typical Action | |---|---|---|---| | I | Non-diagnostic | 5-10% | Repeat FNA in 4-6 weeks | | II | Benign | 0-3% | Follow-up ultrasound in 12-24 months | | III | AUS/FLUS | 10-30% | Repeat FNA or molecular testing (Afirma, ThyroSeq) | | IV | Follicular neoplasm | 25-40% | Molecular testing or diagnostic lobectomy | | V | Suspicious for malignancy | 50-75% | Surgery (lobectomy or thyroidectomy) | | VI | Malignant | 97-99% | Surgery; extent based on tumor characteristics | --- ## Step 5: Special Populations **Pregnancy:** - TSH target: trimester-specific (<2.5 first trimester recommended by ATA) - Increase levothyroxine by 25-30% as soon as pregnancy confirmed - Check TSH every 4 weeks through week 20 - TPO-positive women at higher risk for postpartum thyroiditis **Elderly (>65 years):** - TSH target less aggressive (1.0-5.0 acceptable per individual risk) - Over-treatment causes atrial fibrillation, osteoporosis, and falls - Start levothyroxine at low dose (25-50 mcg); titrate slowly **Amiodarone-induced thyroid dysfunction:** - Type 1: iodine-induced hyperthyroidism (underlying thyroid disease) - Type 2: destructive thyroiditis (no underlying disease) - Both require endocrinology consultation --- ## Checkpoint B: Post-Draft Alignment (Mandatory) 1. Is the TSH interpretation placed in clinical context (medications, pregnancy, illness)? 2. Is the levothyroxine dose appropriate for the patient's weight, age, and cardiac status? 3. Has thyroid nodule been risk-stratified using TI-RADS with appropriate FNA decision? 4. Are monitoring intervals specified for the current management phase? 5. Has endocrinology referral been considered for complex cases (hyperthyroidism, nodules, pregnancy)? --- ## Quality Audit - [ ] TSH interpretation accounts for interfering factors (biotin, illness, pregnancy, medications) - [ ] Free T4 ordered when TSH is abnormal (not just TSH alone) - [ ] TPO antibodies checked for subclinical hypothyroidism to predict progression - [ ] Levothyroxine dose calculated per body weight or started conservatively if elderly/cardiac - [ ] Administration instructions documented (empty stomach, separation from interfering agents) - [ ] Monitoring interval appropriate (6-8 weeks during titration; 6-12 months when stable) - [ ] Subclinical hypothyroidism treatment decision documented with rationale - [ ] Thyroid nodule evaluated with ultrasound using TI-RADS before FNA decision - [ ] FNA threshold applied correctly based on TI-RADS category and size - [ ] Bethesda result documented with appropriate follow-up plan - [ ] Hyperthyroidism workup includes TSI/TRAb and consideration of RAIU scan - [ ] Pregnancy-specific TSH targets applied with appropriate dose adjustment - [ ] Endocrinology referral triggered for hyperthyroidism, Bethesda III+, pregnancy complications, or amiodarone-induced disease - [ ] Thyroid cancer surveillance plan documented if post-thyroidectomy --- ## Guidelines - Never order thyroid ultrasound for abnormal TSH alone; ultrasound is indicated for palpable nodules, incidental imaging findings, or risk stratification of known nodules—not for screening - Subclinical hypothyroidism (TSH 4-10, normal FT4) does NOT always require treatment; over-treatment in the elderly causes atrial fibrillation and osteoporosis - Biotin (vitamin B7) at doses >5mg/day causes false TSH results on many immunoassays; always ask about biotin supplements before interpreting thyroid labs - T3 (liothyronine) supplementation is not recommended by ATA for routine hypothyroidism management; evidence for combination T4/T3 therapy is insufficient - Levothyroxine is the fourth most prescribed medication in the U.S.; dose changes of 12.5-25 mcg are clinically significant and require TSH rechecking - Incidental thyroid nodules on CT, MRI, or PET require ultrasound follow-up; PET-avid nodules have a malignancy risk of approximately 35% and warrant FNA regardless of size - Never stop antithyroid medications abruptly without endocrinology guidance; Graves disease relapse occurs in 50-60% after a standard 12-18 month course - Postpartum thyroiditis (occurring in 5-10% of women, higher in TPO-positive) typically presents as transient hyperthyroidism followed by hypothyroidism; monitor closely for permanent hypothyroidism